- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MEDICENNA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.08. | Stocks in Play: Medicenna Therapeutics Corp. | - | Baystreet.ca | ||
| 14.08. | Medicenna Therapeutics Corp. GAAP EPS of -$0.06 | 1 | Seeking Alpha | ||
| 02.07. | Medicenna stock price target maintained at $2.50 by H.C. Wainwright | 2 | Investing.com | ||
| 26.06. | Medicenna Therapeutics Corp. GAAP EPS of -C$0.22 | 1 | Seeking Alpha | ||
| 26.06. | Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights | 250 | GlobeNewswire (Europe) | MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer... ► Artikel lesen | |
| 11.06. | Medicenna Therapeutics Corp: Medicenna receives two U.S. patents | 1 | Stockwatch | ||
| 03.06. | Medicenna Therapeutics Corp: Medicenna highlights MDNA11 melanoma trial data | 3 | Stockwatch | ||
| 03.06. | Stocks in Play: Medicenna Therapeutics Corp. | 1 | Baystreet.ca | ||
| 29.05. | Medicenna Therapeutics Corp: Medicenna Therapeutics closes $4.44M public offering | 1 | Stockwatch | ||
| 28.05. | Medicenna Therapeutics Corp.: Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs | 1 | GlobeNewswire (USA) | ||
| 22.05. | Medicenna Therapeutics Corp: Medicenna files prospectus for $5-million offering | 1 | Stockwatch | ||
| 22.05. | Medicenna Therapeutics Corp.: Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet | 3 | GlobeNewswire (USA) | ||
| 19.05. | Medicenna Therapeutics Corp: Medicenna sets out terms of public offering | 1 | Stockwatch | ||
| 19.05. | Stocks in Play: Medicenna Therapeutics Corp. | 1 | Baystreet.ca | ||
| 19.05. | Medicenna prices public offering at $0.50 per unit | 5 | Investing.com | ||
| 13.05. | Medicenna launches public offering to fund clinical programs | 2 | Investing.com | ||
| 13.05. | Medicenna launches marketed public offering of securities | 1 | Seeking Alpha | ||
| 13.05. | Medicenna Therapeutics Corp.: Medicenna Announces the Launch of a Marketed Public Offering of Securities | 1 | GlobeNewswire (USA) | ||
| 12.05. | Stocks in Play: Medicenna Therapeutics Corp. | 2 | Baystreet.ca | ||
| 12.05. | Medicenna Therapeutics Corp.: Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma | 203 | GlobeNewswire (Europe) | NEO-CYT marks the first evaluation of MDNA11 in earlier-stage cancers, as a potentially curative treatment; extends development beyond the heavily pretreated metastatic setting of the ongoing Phase... ► Artikel lesen |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 135,09 | +0,01 % | Biotech Stocks At 52-Week Highs - MiniMed Group +10%, Pulse Biosciences, Solventum, Royalty Pharma, Apogee Therapeutics | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on September 1, 2026, as various companies reported financial results and reached certain regulatory milestones.MiniMed... ► Artikel lesen | |
| BIOAFFINITY TECHNOLOGIES | 9,770 | +0,21 % | 6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More | BEIJING (dpa-AFX) - Today's after-hours gainers in the healthcare sector included Universe Pharmaceuticals, which drew attention after disclosing multiple Schedule 13G filings; bioAffinity Technologies... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,600 | 0,00 % | Summit Therapeutics in focus as its lung cancer drug shows survival benefit | ||
| AMYLYX PHARMACEUTICALS | 34,490 | 0,00 % | Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? | ||
| COGENT BIOSCIENCES | 34,570 | 0,00 % | Cogent Biosciences, Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 82,83 | +0,08 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth | Generated second quarter 2026 XDEMVY- net product sales of $173.9 million, an increase of more than 69% year-over-year Increased full-year 2026 XDEMVY net product sales guidance to $685-705 million... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 14,940 | 0,00 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population | After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years 4D-150 continues to be well tolerated... ► Artikel lesen | |
| ALUMIS | 10,330 | -0,19 % | Alumis Inc.: Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE) | - LUMUS trial did not meet its primary and secondary endpoints in the overall trial population - - Robust responses in the prespecified subgroup of patients with high interferon gene signature (IFNGS-high)... ► Artikel lesen | |
| QIAGEN | 38,155 | +2,14 % | QIAGEN N.V.: QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction | New IVD automation platform standardizes nucleic acid extraction across diverse assay workflows with improved productivity, sample traceability and process safety Builds on more than 3... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 11,500 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48... ► Artikel lesen | |
| IMMUNOME | 27,330 | 0,00 % | Immunome: Varegacestat Cuts Progression Or Death Risk 84% As FDA Decision Targets April 2027 | ||
| KYMERA THERAPEUTICS | 118,72 | +0,08 % | Guggenheim raises Kymera Therapeutics price target to $170 on STAT6 program | ||
| ERASCA | 16,380 | +0,06 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 357,94 | +0,12 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 29,050 | +0,03 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | - PDUFA target date of December 22, 2026 for lorundrostat; commercial preparations on-track for launch upon approval - - Appoints accomplished cardiovascular medicine executive Dr. Terry Ferguson... ► Artikel lesen |
MEDICENNA THERAPEUTICS CORP gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICENNA THERAPEUTICS CORP finden Sie auf Wallstreet Online.